Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 1, 2000, Pages 123-130

  Szczech, G M ^a   Furman, P ^a   Painter, G R ^a   Barry, D W ^a   Borroto Esoda, K ^a   Grizzle, T B ^a   Blum, M R ^a   Sommadossi, J P ^b   Endoh, R ^c   Niwa, T ^c   Yamamoto, M ^c   Moxham, C ^a  

^a Triangle Pharmaceuticals   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Research Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; EMIVIRINE; LIVER ENZYME; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TISSUE LEVEL; FEMALE; GENOTOXICITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; LIVER MICROSOME; LIVER WEIGHT; MALE; MITOCHONDRION; MONKEY; MOUSE; NEPHROTOXICITY; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RABBIT; RAT; REPRODUCTIVE TOXICITY; STEM CELL;

EID: 0033986850     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.1.123-130.2000     Document Type: Article

References (37)

1. Ames, B. N., F. D. Lee, and W. E. Durston. 1973. An improved bacterial test System for the detection and classification of mutagens and carcinogens. Proc. Natl. Acad. Sci. USA 70:782-786.
2. Baba, M., E. DeClerq, and S. Iida. 1990. Anti-human immunodeficiency virus type 1 activities and pharmacokinetics of novel 6-substituted acyclouridine derivatives. Antimicrob. Agents Chemother. 34:2358-2363.
3. Baba, M., S. Shigeta, S. Yuasa, H. Takashima, K. Sekiya, M. Ubasawa, H. Tanaka, T. Miyasaka, R. T. Walker, and E. De Clercq. 1994. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 38:688-692.
4. Baba, M., S. Yuasa, T. Niwa, M. Yamamoto, S. Yabuuchi, H. Takashima, M. Ubasawa, H. Tanaka, T. Miyasaka, R. T. Walker, J. Balzarini, E. De Clercq, and S. Shigeta. 1993. Effect of human serum on the in vitro anti HIV-1 activity of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)-thymidine (HEPT) derivatives as related to their lipophilicity and serum protein binding. Biochem. Pharmacol. 45:2507-2512.
5. Balzarini, J., H. Pelemans, M.-J. Perez-Perez, A. San-Felix, M.-J. Camarasa, E. De Clercq, and A. Karlsson. 1996. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2′,3′-dideoxy-3′-thiacytidine. Mol. Pharmacol. 49:882-890.
6. Berger, A. R., J. C. Arezzo, H. H. Schaumburg, G. Skowron, T. Merigan, S. Bozzette, D. Richman, and W. Soo. 1993. 2′,3′-Dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 43:358-362.
7. Brennan, T. M., D. L. Taylor, C. G. Bridges, J. P. Leyda, and A. S. Tyms. 1995. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor, MKC-442, alone and in combination with other anti-HIV compounds. Antivir. Res. 26:173-187.
8. Bruning, J. L., and B. L. Kintz. 1987. Pearson product-moment correlation, p. 176-180. In Computational handbook of statistics, 3rd ed. Harper Collins Publishers, Glenview, Ill.
9. Chiba, M., M. Hensleigh, J. Nishime, S. Balani, and J. Lin. 1996. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24:307-313.
10. Cui, L., S. Schinazi, G. Gosselin, J.-L. Imbach, C. K. Chu, R. F. Rando, G. R. Revankar, and J.-P. Sommadossi. 1996. Effect of β enantiomeric and racemic nucleoside analogs on mitochondrial functions in HepG2 cells: implications for predicting drug hepatotoxicity. Biochem. Pharmacol. 52:1577-1584.
11. De Clerq, E. 1993. HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Med. Res. Rev. 13:229-258.
12. De Clerq, E. 1998. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antivir. Res. 38:153-179.
13. De Clerq, E. 1996. What can be expected from non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the treatment of human immunodeficiency virus type 1 (HIV-1) infections? Med. Virol. 6:97-117.
14. De Clerq, E., and J. Balzarini. 1995. Knocking out human immunodeficiency virus through non-nucleoside reverse transcriptase inhibitors used as single agents or in combinations: a paradigm for the cure of AIDS? Il Pharmaco 50:735-747.
15. Embretson, J., M. Zupancic, J. L. Ribas, A. Burke, P. Ratz, K. Tenner-Racz, and A. T. Haase. 1993. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362: 359-362.
16. Furman, P. A., and C. Moxham. 1998. MKC-442: a potent and selective non-nucleoside reverse transcriptase inhibitor. Drugs Future 23:718-724.
17. Graul, A., X. Rabasseda, and J. Castan̄er. 1998. Efavirenz. Drugs Future 23:133-141.
18. Habteyesus, A., A. Nordenskjold, C. Bohman, and S. Eriksson. 1991. Deoxynucleoside phosphorylating enzymes in monkey and human tissues show great similarities, while mouse deoxycytidine kinase has a different substrate specificity. Biochem. Pharmacol. 42:1829-1836.
19. Hayashi, M., T. Morita, Y. Kodama, T. Sofuni, and M. Ishidate. 1990. The micronucleus assay with mouse peripheral blood reticulocytes using acridine orange-coated slides. Mutat. Res. 245:245-249.
20. 3 from rat liver microsomes. J. Biochem. 99:1753-1763.
21. Hopkins, A. L., R. Jingshan, R. M. Esnouf, B. E. Willcox, E. Yvonne Jones, C. Ross, T. Miyasaka, R. T. Walker, H. Tanaka, D. K. Stammers, and D. I. Stuart. 1996. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem. 39:1589-1600.
22. Kilby, J. M., and M. S. Saag. 1994. Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection? Infect. Agents Dis. 3:313-323.
23. Li, A. P., J. H. Carver, W. N. Choy, A. W. Hsie, R. S. Gupta, K. S. Loveday, J. P. O'Neill, J. C. Riddle, L. F. Stankowski, and L. L. Yang. 1987. A guide for the performance of the Chinese hamster ovary cell hypoxanthine-guanine phosphoribosyl transferase gene mutation assay. Mutat. Res. 189:135.
24. McLaren, C., R. Datema, C. A. Knupp, and R. A. Buroker. 1991. Review: didanosine. Antivir. Chem. Chemother. 2:321-328.
25. Merluzzi, V. J., K. D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J. C. Wu, C.-K. Shih, K. Eckner, S. Hattox, J. Adams, A. S. Rosehthal, R. Faanes, R. J. Eckner, R. A. Koup, and J. L. Sullivan. 1990. Inhibition of HIV-1 replication by a non-nucleoside reverse transcriptase inhibitor. Science 250: 1411-1413.
26. Murphy, R. L., and J. Montaner. 1996. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp. Opin. Investig. Drugs 5:1183-1199.
27. Okamoto, M., M. Makino, K. Yamada, K. Nakade, S. Yuasa, and M. Baba. 1996. Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1-infected cells. Antivir. Res. 31:69-77.
28. Pantaleo, G., C. Graziosi, J. F. Demarest, L. Butini, M. Montroni, C. H. Fox, J. M. Orenstein, D. P. Kotler, and A. S. Fauci. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355-358.
29. Patel, S. S., and P. Benfield. 1996. Nevirapine. Clin. Immunother. 6:307-317.
30. Pialoux, G., S. Fournier, A. Moulignier, J.-D. Poveda, F. Clavel, and B. Dupont. 1997. Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudineand indinavir. AIDS 11:1302-1303.
31. Piras, G., K. Nakade, S. Yuasa, and M. Baba. 1997. Three-drug combinations of MKC-442, lamivudine, and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1. AIDS 11:469-475.
32. Seki, M., Y. Sadakata, S. Yuasa, and M. Baba. 1995. Isolation and characterization of human immunodeficiency virus type 1 mutants resistant to the non-nucleoside reverse transcriptase inhibitor MKC-442. Antivir. Chem. Chemother. 6:73-79.
33. Sommadossi, J.-P., R. Carlisle, R. F. Schinazi, and Z. Zhou. 1988. Uridine reverses the toxicity of 3′-azido-3′-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrob. Agents Chemother. 32:997-1001.
34. Swindells, S., and H. E. Gundelman. 1996. The new non-nucleoside reverse transcriptase inhibitors. Infect. Med. 13:715-719.
35. Wie, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 273:117-122.
36. Yasumori, T., K. Nagata, S. Yang, L. Chen, N. Murayama, Y. Yamazoe, and R. Kato. 1993. Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in a substrate concentration-dependent manner. Pharmacogenetics 3:291-301.
37. Yuasa, S., Y. Sadakata, H. Takashima, S. Kouichi, N. Inouye, M. Ubasawa, and M. Baba. 1993. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442. Mol. Pharmacol. 44:895-900.